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B I O C H E M I S T R Y
Structural insights into ADP-ribosylation of ubiquitin by 
Deltex family E3 ubiquitin ligases
Chatrin Chatrin1,2*, Mads Gabrielsen1*, Lori Buetow1, Mark A. Nakasone1, Syed F. Ahmed1, 
David Sumpton1, Gary J. Sibbet1, Brian O. Smith3, Danny T. Huang1,2†
Cellular cross-talk between ubiquitination and other posttranslational modifications contributes to the regulation 
of numerous processes. One example is ADP-ribosylation of the carboxyl terminus of ubiquitin by the E3 DTX3L/
ADP-ribosyltransferase PARP9 heterodimer, but the mechanism remains elusive. Here, we show that independently 
of PARP9, the conserved carboxyl-terminal RING and DTC (Deltex carboxyl-terminal) domains of DTX3L and other 
human Deltex proteins (DTX1 to DTX4) catalyze ADP-ribosylation of ubiquitin’s Gly76. Structural studies reveal a 
hitherto unknown function of the DTC domain in binding NAD+. Deltex RING domain recruits E2 thioesterified with 
ubiquitin and juxtaposes it with NAD+ bound to the DTC domain to facilitate ADP-ribosylation of ubiquitin. This 
ubiquitin modification prevents its activation but is reversed by the linkage nonspecific deubiquitinases. Our 
study provides mechanistic insights into ADP-ribosylation of ubiquitin by Deltex E3s and will enable future studies 
directed at understanding the increasingly complex network of ubiquitin cross-talk.
INTRODUCTION
Reversible posttranslational modifications (PTMs) are used by 
eukaryotic cells to dynamically regulate signaling events (1). Attach-
ment of PTMs rapidly alters the properties of a protein and, by ex-
tension, its functions. While a single PTM is capable of achieving 
this purpose, many proteins are modified by several PTMs, which 
exponentially increases the number of possible biological consequences 
(2). Another layer complexity is achieved when ubiquitin (Ub), itself 
a PTM, is modified by phosphorylation, deamidation, acetylation, 
or adenosine 5′-diphosphate (ADP)–ribosylation (3). A number of 
studies have shown that cross-talk occurs between ubiquitination 
and poly-ADP-ribosylation (PARylation) whereby PARylation serves 
as a signal to target substrates for polyubiquitination and subsequent 
degradation (4–6). In addition, ADP-ribosylation of Ub on Arg42 by 
Legionella pneumophila SidE family proteins or on Gly76 by the 
complex comprising E3 Deltex-3-like protein ligase (DTX3L) and pro-
tein mono-ADP-ribosyltransferase poly(ADP-ribose) polymerase 9 
(PARP9) has been shown to modulate ubiquitination (7–9).
In mammals, three families of proteins are primarily responsible 
for attaching and removing ADP-ribose moieties during ADP- 
ribosylation–dependent signaling events. The PARP family of proteins, 
of which PARP9 is a member, catalyzes the transfer of ADP-ribose 
to target proteins, whereas ADP-ribosylglycohydrolases and macro-
domains remove these signals. PARPs share an evolutionarily con-
served catalytic domain essential for binding NAD+ (nicotinamide 
adenine dinucleotide). These enzymes transfer one or more moieties 
of ADP-ribose from NAD+ to substrate while releasing nicotinamide, 
resulting in mono-ADP-ribosylated (MAR) or poly-ADP-ribosylated 
(PAR) substrates. ADP-ribose can be transferred to side chains with 
a nucleophilic nitrogen, oxygen, or sulfur atom to generate an N-, O-, 
or S-glycosidic linkage, respectively (10, 11). Moreover, an O-glycosidic 
linkage can also form on the C-terminal carboxylate. Although 
PARP9 is a member of the PARP family, it lacks catalytic activity in 
auto-ADP-ribosylation assays (12).
PARP9 binds DTX3L (13), which shares a conserved C terminus 
with Deltex proteins that comprises a RING finger domain and 
a ~150-residue Deltex C-terminal (DTC) domain of unknown func-
tion (14). The presence of a RING finger domain is characteristic of 
RING-type E3 ligases, which bind E2~Ub thioester intermediate 
(~ indicates a thioester bond) and facilitate transfer of the C terminus of 
Ub directly from E2~Ub to substrate (15). The sequential actions of the 
E1-E2-E3 enzyme cascade are required to achieve ubiquitination (16, 17). 
E1 uses Mg2+–adenosine 5′-triphosphate (ATP) to activate and then trans-
fer the C terminus of Ub to E2’s catalytic cysteine to form E2~Ub. E3s then 
catalyze transfer of the C terminus of Ub to the side chain of a lysine residue 
on substrate (18). Like other PTMs, ubiquitination on a substrate is 
reversible and is removed by deubiquitinases (DUBs) (19).
We wanted to investigate how the cross-talk between ADP- 
ribosylation and ubiquitination is mediated by the DTX3L/PARP9 
heterodimer. Previously, the formation of ADP-ribosylated–Ub 
(ADPr-Ub) was reported to depend on both the RING domain of 
DTX3L and the catalytic domain of PARP9. However, we unexpect-
edly found that the E3 ligase DTX3L alone was sufficient to catalyze 
ADP-ribosylation of Ub in the presence of NAD+ and components of 
the ubiquitination cascade. By truncating DTX3L, we pinpointed 
that the RING and DTC (hereafter referred to as RD) domains were 
the minimum subunit required to perform this reaction. Because 
this region is conserved in the Deltex family, we tested all its mem-
bers and found that they share this ability to ADP-ribosylate Ub. 
We hypothesized that the RD domains have to physically interact 
with both NAD+ and E2~Ub, and using DTX1, we demonstrated 
that the conserved DTC domain binds NAD+. We found that ADPr- 
Ub generation by DTX1 relies on NAD+ binding to the DTC do-
main, E2~Ub recruitment by the RING domain, and the structural 
arrangement of the two domains. This Ub modification is suscepti-
ble to removal by the linkage nonspecific DUB Ub-specific protease 
2 (USP2), thereby revealing the dynamic nature of this signal. Over-
expression of DTX2 in human embryonic kidney (HEK) 293 cells 
could overcome signal removal by DUBs and allowed us to detect 
an ADPr-Ub signal in a cellular environment.
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RESULTS
Deltex proteins catalyze ADP-ribosylation of Ub
To elucidate the mechanism of Ub ADP-ribosylation by DTX3L/
PARP9, we initially used 32P-NAD+ or biotin-NAD+ to follow the 
formation of 32P-ADPr-Ub or biotin-ADPr-Ub, respectively, in the 
presence of E1, the E2 UbcH5B, Mg2+-ATP, and DTX3L/PARP9 
complex, DTX3L or PARP9 (Fig. 1A and fig. S1A). As previously 
reported (9), ADPr-Ub formed with DTX3L/PARP9 complex but 
not with PARP9 alone; unexpectedly, however, DTX3L alone was 
sufficient to generate ADPr-Ub. DTX3L has three predicted N-terminal 
domains (D1, D2, and D3), a RING domain bearing its ligase activity, 
and a DTC domain of unknown function (Fig. 1B). To map the do-
main or domains responsible for ADP-ribosylation of Ub, we tracked 
the formation of ADPr-Ub by truncated DTX3L variants and found 
that the minimum fragment comprised the RD domains; neither 
the RING nor DTC domain alone formed 32P-ADPr-Ub (Fig. 1A) 
or biotin-ADPr-Ub (fig. S1A). To further probe requirements for 
ADP-ribosylation of Ub by DTX3L, we omitted each reactant indi-
vidually (E1, E2, Mg2+-ATP, and biotin-NAD+) and tracked biotin- 
ADPr-Ub formation. Formation of biotin-ADPr-Ub by full-length 
DTX3L (DTX3L-FL) or DTX3L-RD required the presence of a com-
plete set of ubiquitination cascade components (E1, E2 UbcH5B, 
Mg2+-ATP, and Ub) and NAD+ (Fig. 1, C and D).
Given that the RD domains are the defining characteristic of the 
Deltex family of E3s (Fig. 1B), we next investigated whether ADP- 
ribosylation of Ub is a general feature of this family. ADPr-Ub for-
mation was observed in assays with each of the five Deltex RD 
domains but not with RING domains from other E3s such as pCBL 
(phosphorylated-Tyr371 Casitas B-lineage lymphoma protein), 
RNF38 (RING finger protein 38), or BIRC7 (baculoviral inhibitor of 
apoptosis protein repeat-containing protein 7) (Fig. 1E). In addition, 
we also confirmed that like DTX3L, DTX1-RD and DTX2-RD depend 
on a complete set of ubiquitination cascade components and NAD+ 
to form ADPr-Ub (fig. S1, B and C). Together, our results reveal a 
previously unknown function of the Deltex proteins in catalyzing 
ADP-ribosylation of Ub through their RD domains.
The DTC domain of Deltex accommodates NAD+
Building on our finding that ADP-ribosylation of Ub by Deltex RD 
domains relies on NAD+ and components of the ubiquitination cas-
cade, we hypothesized that the DTX1-RD needs to (i) accommodate 
NAD+ and (ii) recruit E2~Ub. To investigate whether Deltex RD 
domains bind NAD+, we purified 15N-DTX1-RD and acquired 1H-15N 
heteronuclear single-quantum coherence (HSQC) spectra of 15N-DTX1-
RD alone and in the presence of NAD+ (Fig. 2A). Chemical shift 
perturbations (CSPs) induced upon the addition of NAD+ suggest 
that it binds DTX1-RD.
To gain further insight into the RD domains and how they 
accommodate NAD+, we determined crystal structures of the DTX1-RD 
alone and in a complex with NAD+ to 1.88 and 1.74 Å, respectively 
(Fig. 2, B and C, and Table 1). The structure of the RING domain 
resembles the nuclear magnetic resonance (NMR) structures of 
mouse [Protein Data Bank (PDB): 1V87] and human (PDB: 6IR0) 
DTX2 RING domain [root mean square deviation (RMSD) values 
of 0.938 Å across 71 C atoms and 1.237 Å across 55 C atoms, re-
spectively], and the DTC domain resembles the crystal structure of 
human DTX3L DTC domain (PDB: 3PG6; RMSD value of 0.603 Å 
across 111 C atoms). In both the apo and complex structures, the 
RING domain is connected to the DTC domain by a short five–amino 
acid linker, and this conformation does not shift upon binding NAD+ 
(RMSD value of 0.184 Å across 222 C atoms). NAD+ binds to a 
pocket in the DTC domain (Fig. 2D) in which it adopts a compact 
conformation such that the adenine amino group forms a hydrogen 
bond with the C3 hydroxyl group of the nicotinamide ribose moiety 
(Fig. 2D and fig. S2, A and B). The adenine ring is stabilized by 
-stacking interactions with aromatic side chains of Trp577 and His593. 
In addition, hydrogen bonds are observed between Thr584 and N1 
of the adenine ring and between His581 and the adenosine ribose. 
The pyrophosphate forms hydrogen bonds with side chains of Arg534 
and Ser566 and backbone amides of Asn567 and Thr568.
Sequence alignment of the Deltex RD domains reveals that the 
aforementioned residues involved in binding NAD+ are identical 
(Fig. 2E and fig. S2C), except for His593, Asn567, and Thr568. How-
ever, differences in these three residues should not affect NAD+ 
binding. In other Deltex proteins, His593 is conserved as an aro-
matic residue and can putatively form -stacking interactions with 
the adenine ring. Because only the backbone amides of Asn567 and 
Thr568 play a role in binding NAD+, the side chain properties are 
likely to be negligible. High sequence conservation in the binding 
pocket suggests that Deltex proteins are likely to bind NAD+ in a 
similar manner.
To validate the NAD+-binding motif observed in our structure, 
we purified DTX1-RD H581A and H593A mutants and tested their 
ability to form ADPr-Ub. Both variants were defective in promot-
ing ADP-ribosylation of Ub (Fig. 2F) but did not affect E3 ligase 
activity, as demonstrated by the discharge of Ub from UbcH5B~Ub 
to l-lysine (fig. S2, D and E). Together, these results show that 
DTX1-RD binds NAD+ via the DTC domain to prime NAD+ for 
ADPr-Ub formation.
RING domain of Deltex interacts with E2~Ub
We next scrutinized our second hypothesis that ADP-ribosylation 
of Ub by RD domains requires E2~Ub recruited in a RING domain–
dependent manner. Initially, we tested whether this fragment 
was capable of promoting ubiquitination. Sequence alignment of 
the conserved RD region from Deltex family proteins (fig. S2C) re-
veals the absence of a RING domain “linchpin” arginine that helps 
promote the closed E2~Ub conformation in which Ub is primed 
for transfer (18, 20). To assess whether Deltex fragments en-
compassing the RD domains or RING domain were active in Ub 
transfer, we purified glutathione S-transferase (GST)–tagged 
DTX1-RD and DTX1-RING and showed that both are competent 
in autoubiquitination despite lacking a linchpin arginine (Fig. 3A 
and fig. S3A).
To test our hypothesis that the RING domain is responsible for 
recruiting E2~Ub in the RD domain–catalyzed reaction, we exam-
ined the formation of ADPr-Ub in the presence of 32P-NAD+ with 
UbcH5B F62A P95D, an E2 variant that cannot bind the RING do-
main (21), and DTX1-RD I413A Y424A, a RING variant suggested 
to impair interactions with E2 based on similarities to other RING 
E3s (fig. S3B). Ile413 in DTX1 is equivalent to Ile440 in MDM2 (mu-
rine double minute 2) and Ile26 in BRCA1 (breast cancer type 1 sus-
ceptibility protein), and this residue has been demonstrated to be 
important for binding E2 in both of these RING E3s (22, 23). The 
UbcH5B and DTX1-RD mutants both showed defects in Ub transfer 
and abolished ADP-ribosylation of Ub (Fig. 3B and fig. S3, C to F). 
Thus, the ability of the DTX1 RING domain to recruit E2~Ub is 
required for ADPr-Ub formation.
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Fig. 1. All Deltex E3s ADP-ribosylate Ub via the RING-DTC domains. (A) Reduced autoradiogram showing Ub ADP-ribosylation reactions with DTX3L and PARP9 variants 
in the presence of E1, E2 UbcH5B, Mg2+-ATP, Ub, and 32P-NAD+. The reaction scheme is shown above, where E2~Ub was first generated before the addition of E3 and 
NAD+ to initiate the reaction. (B) Domain organization of the Deltex family of E3s. All members share adjoining C-terminal RD domains. DTX1, DTX2, and DTX4 have tandem 
WWE domains at the N terminus and C3H2C3-type RING fingers. DTX3 and DTX3L have C3HC4-type RING fingers. DTX3L has a unique N-terminal region that mediates its 
interaction with PARP9, while DTX1 to DTX4 contain a proline-rich region in domain D. (C) Western blot of in vitro Ub ADP-ribosylation reactions in which E1, E2 UbcH5B, 
Ub, Mg2+-ATP, or full-length DTX3L (DTX3L-FL) has been omitted as indicated in the presence of biotin-NAD+ and separated by SDS–polyacrylamide gel electrophoresis 
(PAGE) in reducing conditions. (D) As in (C), but with DTX3L-RD. (E) Western blot of in vitro reactions with E1, E2 UbcH5B, Mg2+-ATP, Ub, biotin-labeled NAD+, and the in-
dicated Deltex protein RING-DTC domains, pCBL, RNF38, or BIRC7 separated by SDS-PAGE in reducing conditions. For (C) to (E), -Ub is shown in red, and NeutrAvidin 
DyLight is shown in green.
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Fig. 2. DTX1 DTC domain binds NAD+. (A) 1H-15N HSQC spectra of 15N-DTX1-RD (black) and after the addition of NAD+ (green). ppm, parts per million. (B) Cartoon 
representation of the structure of the DTX1-RD. The RING, linker, and DTC domains are colored green, cyan, and magenta, respectively. Zn2+ atoms are depicted as gray 
spheres. (C) Structure of DTX1-RD bound to NAD+. DTX1-RD is colored as in (B) and in the same orientation. NAD+ is shown in sticks with C atoms colored yellow, O atoms 
colored red, N atoms colored blue, and P atoms colored orange. (D) Close-up view of NAD+-binding site corresponding to the region outlined in (C) (left). A different close-up 
view of the NAD+-binding site is shown in the right panel. Key NAD+-binding residues are shown in sticks, and atoms are colored as in (C). Black dashes indicate hydrogen 
bonds. (E) The DTX1-RD is shown as a surface representation with identical and conserved residues from the sequence alignment in fig. S2C colored black and gray, re-
spectively. The RING, linker, and DTC domains are colored light green, cyan, and light pink, respectively. (F) Western blot (top) and Ponceau stain (bottom) of in vitro 
ADP-ribosylation reactions with DTX1-RD wild-type (WT) or indicated variants in the presence of E1, UbcH5B, Mg2+-ATP, Ub, and 32P-NAD+. Reactions without ATP were 
used to show similar E3 loading.
 on N
ovem
ber 18, 2020
http://advances.sciencem
ag.org/
D
ow
nloaded from
 
Chatrin et al., Sci. Adv. 2020; 6 : eabc0418     18 September 2020
S C I E N C E  A D V A N C E S  |  R E S E A R C H  A R T I C L E
5 of 14
Subsequently, we examined the effects of disrupting the primed 
UbcH5B~Ub conformation required for canonical Ub transfer on 
the formation of ADPr-Ub. We mutated key residues involved in 
maintaining the closed conformation, including Ub’s Ile44 to Ala and 
UbcH5B’s Ile88 to Ala or Ser108 to Arg, which were previously shown 
to hinder RING E3-mediated Ub transfer (21, 24). These mutants 
diminished Ub transfer activity in DTX1-RD autoubiquitination 
assays (fig. S3, G to I) and also abrogated ADP-ribosylation of Ub 
(Fig. 3C). Collectively, these data suggest that the DTX1 RING do-
main binds UbcH5B~Ub in the canonical closed conformation to 
promote the formation of ADPr-Ub.
Ub ADP-ribosylation depends on Deltex  
RING-DTC conformation
Our data demonstrate that priming of E2~Ub for Ub transfer by the 
RING domain and recruitment of NAD+ by the DTC domain are 
indispensable for ADPr-Ub formation. However, whether the 
arrangement of the two domains relative to one another is critical 
for this reaction is unclear. In DTX3L, neither the RING nor the 
DTC domain alone catalyzed ADP-ribosylation of Ub (Fig. 1A). 
Likewise, in DTX1, neither domain alone was sufficient to promote 
the formation of ADPr-Ub (Fig. 4A). Furthermore, when we titrated 
DTX1-RING with excess DTX1-DTC domain in trans, the ability to 
form ADPr-Ub was not restored (Fig. 4A). Thus, the reaction must 
occur in cis, suggesting that the conformational arrangement of the 
RD domains is crucial.
In all available structures of E2~Ub bound to a RING domain in 
which Ub is primed for transfer, E2~Ub adopts a closed conforma-
tion in which the globular body of Ub is proximal to the E2, and the 
tail of Ub is locked into E2’s active site groove (18, 24, 25). On the basis 
of these similarities, we modeled E2~Ub onto our DTX1-RD-NAD+ 
complex structure (Fig. 4B). In our model, NAD+ is situated ~12 Å 
away from the UbcH5B~Ub thioester bond. We postulated that the 
linker between the RD domains might be sufficiently flexible to bridge 
this gap. To probe its flexibility, we collected small-angle x-ray scatter-
ing (SAXS) data on DTX1-RD in solution. The linear Guinier region 
gave a radius of gyration (Rg) of 24.9 Å, whereas the calculated Rg 
for the crystal structure was 23.5 Å (fig. S4A). The Dmax calculated 
from the P(r) from the solution data was 90 Å, whereas it measured 
74.7 Å in the crystal structure, suggesting that DTX1-RD can adopt 
a more extended conformation in solution.
Next, the crystal structure was split into two separate domains 
[RING (388 to 471) and DTC (479-C)], and the solution structure 
of DTX1-RD was modeled using an ensemble of conformations 
(fig. S4B) (26). Two populations best fit the data: One is a compact 
population with an Rg and Dmax of around 22 and 70 Å, respectively, 
and the second is a population with an Rg and Dmax of 25 and 96 Å, 
respectively (Fig. 4C). These data suggest that the two domains have 
some flexibility in relation to each other in solution (fig. S4C) and 
that there is scope to accommodate binding to E2~Ub or substrates. 
We hypothesize that this flexible linker enables the RD domains to 
sample different positions that bring E2~Ub closer to NAD+.
To assess the importance of linker flexibility, we inserted a Gly-
Gly-Ser linker after G476 (G476-GGS) to alter the linker length or 
mutated G476 and E477 to proline (G476P E477P) to restrict the 
rotational flexibility. Both mutants exhibited comparable E3 activ-
ity in discharging E2~Ub as wild-type DTX1-RD (fig. S4, D and E) 
but failed to ADP-ribosylate Ub (Fig. 4D). These results suggest that 
both precise length and flexibility of the linker connecting the two 
domains are important for ADP-ribosylation of Ub.
Next, we investigated whether ADP-ribosylation of Ub occurs 
on E2~Ub conjugate or after Ub is discharged by using Ub covalently 
linked via its C terminus to the active site of UbcH5B (UbcH5B–Ub) 
with an oxyester linkage (UbcH5B C85S–Ub) or an isopeptide link-
age (UbcH5B C85K–Ub) as a substrate in the presence of DTX1-RD 
and biotin-NAD+. UbcH5B C85K–Ub is not labile, whereas UbcH5B 
C85S–Ub releases Ub slowly on its own and when in the presence of 
a RING domain. Covalently bound Ub from both UbcH5B–Ub com-
plexes was not modified. The formation of biotin-ADPr-Ub was only 
observed when Ub was released from UbcH5B C85S–Ub in the pres-
ence of DTX1-RD (Fig. 4E).
On the basis of these results, we propose the following Ub ADP- 
ribosylation reaction mechanism model by Deltex-RD domains 
(Fig. 4F): (i) The DTC domain binds NAD+, (ii) the RING domain 
recruits E2~Ub and promotes the formation of the closed E2~Ub 
Table 1. Data collection and refinement statistics.  
DTX1-RD DTX1-RD-NAD+
PDB code 6Y5N 6Y5P
Data collection
Space group P212121 P212121
Cell dimensions
a, b, c (Å) 67.49, 86.550, 129.830 66.85, 85.25, 130.95
, ,  (°) 90.0, 90.0, 90.0 90, 90, 90
Resolution (Å) 36.01–1.88 (1.88–1.93)*
66.85–1.74 
(1.79–1.74)*
Rmerge (%) 7.3 (117.0) 5.6 (133.4)
I/I 14.7 (1.4) 16.0 (1.0)
Completeness (%) 100.0 (100.0) 100 (100)
Redundancy 6.6 (6.8) 6.4 (5.9)
Refinement
Resolution (Å) 36.01–1.88 (1.88–1.93)*
65.47–1.74 
(1.79–1.74)*
No. reflections 119069 148052
Rwork/Rfree (%) 18.71/21.05 18.53/21.31
No. atoms
Protein 7128 7144
Ions 4 4
Ligand 140
Water 526 420
B factors (Å2)
Protein 37.26 35.96
Ions 57.68 43.01
Ligand 56.44
Water 45.89 46.42
RMSDs
Bond lengths (Å) 0.011 0.010
Bond angles (°) 1.079 1.103
 *Values in parentheses are for highest-resolution shell.
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conformation favorable for Ub transfer, (iii) the flexible linker allows 
the E2~Ub to be brought into close proximity with NAD+, and (iv) 
this facilitates ADP-ribosylation of Ub upon its release from E2~Ub. 
In our DTX1-RD-NAD+ model with E2~Ub, conserved residues in 
the RD domains are localized to the NAD+ and E2~Ub-binding sites 
(fig. S4F), thus raising the likelihood that our observations in DTX1-
RD are extendable to other Deltex proteins.
ADP-ribosylation of Ub at G76 is reversible
To identify the extent and site of ADP-ribosylation on Ub, we gen-
erated ADPr-Ub and incubated it with the principal PAR-removing 
enzyme poly(ADP-ribose) glycohydrolase (PARG), which hydrolyzes 
the O-glycosidic ribose-ribose 1-2′ bonds between ADP-ribose moi-
eties in PAR but cannot cleave the link between the terminal ADP- 
ribose and protein (27). In the presence of PARG, ADPr-Ub levels 
were not noticeably diminished (fig. S5A). In addition, no differences 
in apparent molecular weight between Ub and purified ADPr-Ub 
were detected by SDS–polyacrylamide gel electrophoresis (PAGE), 
and no band smearing such as that observed in PARP1-mediated 
PARylation reactions was evident (fig. S5B). We next performed the 
ADP-ribosylation reaction using 15N-Ub, purified ADPr-15N-Ub, 
and acquired 1H-15N HSQC spectra. Comparison of the spectra of 
15N-Ub and ADPr-15N-Ub revealed marked CSPs in Ub’s C-terminal 
diglycine motif, with the largest CSP observed for Gly76 (Fig. 5, A and B), 
while no CSPs were observed in control samples without DTX1-RD 
or NAD+ (fig. S5, C and D). These data suggest that Ub is mono- 
ADP-ribosylated on Gly76 and are consistent with previous findings 
by Yang and colleagues (9).
ADPr-Ub modification can be recycled by as-yet unidentified 
factor(s) in cell lysates (fig. S5A) (9). Given that DUBs can hydrolyze 
ester, thioester, and amide linkages at the C terminus of Ub to ex-
pose the C-terminal diglycine motif (28), we reasoned that Ub-linkage 
nonspecific DUBs might hydrolyze ADPr-Ub. We tested a panel of 
DUBs for their ability to remove ADPr from ADPr-Ub: Ub-specific 
proteases (USPs; USP2, USP5, USP7, and USP21), ovarian tumor 
proteases (OTUs; vOTU, OTUB1, OTUD3, and OTULIN), yeast Ub 
C-terminal hydrolase 1 (YUH1), and associated molecule with the 
SH3 (Src homology 3) domain of signal transduction adaptor molecule 
(STAM) (AMSH). Of these, the linkage nonspecific DUBs (USPs, 
vOTU, and YUH1) reduced or eliminated the signal from ADPr-Ub 
(fig. S5E). The addition of USP2 (29) to ADPr-15N-Ub reverted the CSPs 
of Ub’s Gly75 and Gly76 to that observed in 15N-Ub (blue; Fig. 5, 
A and B) and promoted the release of 32P-ADPr or biotin-labeled 
ADPr from 32P-ADPr-Ub (Fig. 5C) or biotin-labeled ADPr-Ub (fig. S5A), 
respectively. Liquid chromatography–mass spectrometry (LC-MS) 
analysis of ADPr-Ub treated with USP2 revealed a peak consistent with 
the release of ADP-ribose, confirmed by comparison to an authentic 
ADP-ribose standard (fig. S6). These results confirm DUBs as factors 
for removing ADPr from ADPr-Ub to yield free Ub and support the 
finding that ADP-ribosylation occurs on the C terminus of Ub.
The unmodified C-terminal diglycine motif of Ub is important 
for its activation and transfer along the E1-E2-E3 cascade (17), and 
any C-terminal modification would render Ub unusable. In contrast 
to unmodified Ub, when purified ADPr-Ub was incubated with 
Uba1 and UbcH5B, no E2~Ub was formed (Fig. 5D). Upon treating 
ADPr-Ub with USP2, Ub was reactivated and formed UbcH5B~Ub 
(Fig. 5D). Considering that the Deltex-RD can carry out both ubiq-
uitination and Ub ADP-ribosylation, we wondered what might 
regulate these two opposing reactions. To probe whether the two 
reactions occur at the same time, we performed GST-DTX1-RD 
+ E1/DTX1-RD/Mg2+-ATP/biotin-NAD+
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Fig. 3. DTX1 RD relies on recruitment of E2~Ub for the formation of ADPr-Ub. (A) Reduced SDS-PAGE gels following autoubiquitination of GST-DTX1-RD over time. 
Ubn, Ub chains of length n. (B) Reduced autoradiogram of Ub ADP-ribosylation reactions with DTX1-RD and UbcH5B variants in the presence of E1, Mg2+-ATP, Ub, and 
32P-NAD+. (C) Western blot of in vitro reactions with E1, Mg2+-ATP, DTX1-RD, and biotin-labeled NAD+ and the indicated UbcH5B or Ub variant, separated with SDS-PAGE 
under reducing conditions; -Ub is shown in red, and NeutrAvidin DyLight is shown in green.
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C85K–Ub with biotin-labeled NAD+ in the presence and absence of DTX1-RD; -Ub is shown in red, and NeutrAvidin DyLight is shown in green. Right: SDS-PAGE gel of 
reactions in the left panel. (F) Proposed mechanism of ADP-ribosylation of Ub’s C terminus by DTX1-RD.
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Fig. 5. Ub ADP-ribosylation on Gly76 is reversible by USP2. (A) 1H-15N HSQC spectra of wild-type 15N-Ub (black), ADPr-15N-Ub (red), and ADPr-15N-Ub following treat-
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length Myc-tagged DTX2 variants as indicated. Probed using -Ub, -actin, and -Myc-tag with 1% of input loaded as a loading control. (G) As in (F), but with Myc-tagged 
DTX2-RD variants.
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autoubiquitination assays in the presence of NAD+. With increas-
ing concentrations of NAD+, ADPr-Ub formation increased, and 
GST-DTX1-RD autoubiquitination decreased (Fig. 5E). These data 
suggest that NAD+ concentration and the presence of linkage non-
specific DUBs can contribute to regulation of these functionally 
divergent reactions.
Detecting ADPr-Ub in a cellular environment
Having characterized ADPr-Ub formation by Deltex proteins in vitro, 
we wanted to determine whether this species exists in a cellular en-
vironment. We sought out conditions in which transient expression 
of Deltex was high to overcome potential difficulties associated with 
cleavage of the ADPr-Ub linkage by DUBs and other as-yet uniden-
tified proteins. Comparison of DTX1 and DTX2 revealed that DTX2 
was better expressed so we opted to use it in our cell-based experi-
ments (fig. S7A). Initially, we confirmed that DTX2-RD is active in 
autoubiquitination assays and that mutations of residues in the 
putative NAD+-binding site abolish ADPr-Ub formation (fig. S7, B 
and C). We used the ADP-ribose binding properties of GST-Af1521 
macro domain (30) to pull down ADP-ribosylated protein from cell 
lysates of HEK293 cells overexpressing DTX2 variants and probed 
for Ub. ADPr-Ub was detected in pull-downs from cells expressing 
wild-type full-length DTX2 (DTX2-FL) or DTX2-RD but not the 
control or the DTX2 mutants expected to be incapable of binding 
NAD+ (Fig. 5, F and G). Approximately 1% of the Ub pool from the 
whole-cell input was present as ADPr-Ub.
DISCUSSION
In the past few years, identifying PTMs of Ub itself has expanded 
our knowledge of the Ub code (3, 31). Recently, Ub was reported to 
be ADP-ribosylated on its C terminus by the E3 ligase/PARP complex 
DTX3L/PARP9 (9), yet how PARP9, an inactive ADP-ribosyltransferase 
(ART), contributed to this reaction was unclear. Here, we show that 
ADP-ribosylation of Ub’s C terminus is carried out by the RD do-
mains of DTX3L and the other Deltex family members. These do-
mains have dual activity in that they recruit E2~Ub and catalyze Ub 
transfer in the canonical fashion of RING E3 ligases, but in the pres-
ence of NAD+, they also promote the formation of ADPr-Ub. ADPr- 
Ub cannot be activated by E1 and therefore cannot be used for 
ubiquitination by the E1-E2-E3 cascade. To form ADPr-Ub, Deltex 
DTC domain binds NAD+, and the RING domain recruits and primes 
E2~Ub in the closed conformation for Ub transfer; when the thioester 
bond of E2~Ub and NAD+ are juxtaposed, ADP-ribosylation of Ub 
proceeds upon release of Ub from E2. The Deltex RD domains en-
able E2~Ub and NAD+ to be in close proximity and thereby facili-
tate ADP-ribosylation of the C-terminal Gly of Ub.
This is the first instance in which a function for the DTC domain 
has been demonstrated. Previously, Yang and colleagues (9) pro-
posed that the catalytic domain of PARP9 in the DTX3L/PARP9 
complex mediates ADP-ribosylation of Ub. However, their obser-
vation was made in the context of DTX3L/PARP9 heterodimer, and 
DTX3L was not tested on its own. We demonstrated that DTX3L 
catalyzed Ub ADP-ribosylation in the absence of PARP9 and further 
showed that the RD domains of other Deltex proteins share this 
function. The role PARP9 plays in modulating the catalytic activity 
of DTX3L requires further investigation.
At least four families of NAD+-binding proteins have previously 
been identified in mammals: ARTs, ADP-ribosylcyclases, sirtuins, 
and oxidoreductases (32). In DTX1-RD-NAD+, the chemical envi-
ronment of the NAD+-binding site is unique compared to these other 
families, suggesting that Deltex proteins comprise a fifth family of 
NAD+-binding proteins. Within these NAD+-binding families, Deltex 
proteins, ARTs, and sirtuins catalyze NAD+-dependent transfer of 
ADP-ribose to substrates by breaking the bond between the nicotin-
amide and ADP-ribose moieties of NAD+ and releasing nicotin-
amide. ARTs and some sirtuins catalyze ADP-ribose via an SN1-like 
mechanism in which nicotinamide leaves, thereby generating an 
oxocarbenium ion intermediate. In other sirtuins, ADP-ribose trans-
fer is proposed to proceed via an SN2-like mechanism. Regardless of 
mechanism, in both these families, the conformation of NAD+ is 
constrained to prime the bond between the nicotinamide and 
nicotinamide-linked ribose for catalysis. Thus, both of these families 
have conserved residues that function to lock these NAD+ moieties 
in place; in contrast, there are very few interactions with these 
moieties in Deltex proteins, suggesting that ADP-ribosylation of 
Ub Gly76 by Deltex RD domains does not follow known ADP- 
ribosylation mechanisms.
In our structural model of DTX1-RD domains bound to E2~Ub 
and NAD+, there is a large distance between the E2~Ub thioester 
bond and NAD+. For ADP-ribosylation of Ub to occur, the E2~Ub 
thioester bond and NAD+ must juxtapose. The DTX1-RD structure 
shows that a five-residue linker separates the RD domains, and the 
length of this linker is strictly conserved across all Deltex proteins. 
Our SAXS analyses show that the RD domains can adopt different 
conformations in solution likely through the flexibility of this linker. 
When we altered the linker length or restricted its flexibility, Ub 
ADP-ribosylation was abolished. Thus, linker length and flexibility 
are crucial in facilitating juxtaposition of RING-bound E2~Ub and 
DTC-bound NAD+ for Ub ADP-ribosylation. Considering that 
the Deltex RING domain also catalyzes substrate ubiquitination, 
the linker flexibility will be essential to bring RING-bound E2~Ub 
away from the NAD+-binding pocket to allow access by the sub-
strate’s lysine.
ADP-ribosylation and ubiquitination both require a nucleophile 
to correspondingly attack NAD+ or E2~Ub. ADP-ribosylation of Ub 
only occurs when Ub is released from E2–Ub as demonstrated by 
our assays with UbcH5B C85S–Ub and UbcH5B C85K–Ub. The 
carbonyl carbon is susceptible to nucleophilic attack, including by 
water, in the oxyester and thioester but not the amide, suggesting 
that the reactivity of the carbonyl carbon is important. We postulate 
that ADPr-Ub formation proceeds via one of two scenarios. In the 
first scenario, the RING-bound E2~Ub is hydrolyzed, thereby re-
leasing the Gly76 carboxylate group, which, in turn, functions as 
a nucleophile in the ADP-ribosylation reaction. Gly76 is ADP- 
ribosylated because of its close proximity with NAD+ bound to the 
DTC domain. In the second scenario, NAD+ is first hydrolyzed into 
nicotinamide and ADP-ribose, and the ribose O1′ then attacks the 
thioester bond.
We show that Deltex RD domains have dual activity. DTX1 and 
DTX2 are active E3 ligases in autoubiquitination assays, and existing 
literature shows that Deltex proteins are active in ubiquitinating substrates 
such as MEKK1 (mitogen-activated protein kinase kinase kinase 1) 
(33) and histones (9, 34, 35). It is therefore intriguing that these RING 
E3 ligases also ADP-ribosylate Ub on Gly76, thereby preventing ubiq-
uitination. While this dual activity seems counterintuitive, it might 
serve as an autoinhibitory mechanism to quench ligase activity. 
Our work and the DTX3L/PARP9 study (9) both show that NAD+ 
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concentrations influence the switch between ubiquitination and 
ADP- ribosylation of Ub in vitro. However, understanding the full 
extent of this dual activity and its regulation requires further study.
The extent of any PTM including ADPr-Ub turnover in the cell 
relies on the forward and reverse reactions (32). Here, we show that 
while ADP-ribosylation of Ub’s Gly76 blocks activation by E1, it is 
reversed by the Ub-linkage nonspecific DUB USP2 (29), suggesting 
a dynamic regulation of this PTM (Fig. 5). This reverse reaction poses 
a challenge in detecting ADPr-Ub in cells. Moreover, ADP-ribose 
itself is a labile and highly charged PTM, making it difficult to iden-
tify as an intact modification using proteomics methods (36). One 
strategy used to enrich for ADP-ribosylated proteins is to perform 
pull-downs with Af1521 macrodomain, which binds ADPr with a 
Kd (dissociation constant) of 130 nM (37). Given that the total Ub 
concentration in HEK293 is ~85 M (38) and that the abundance of 
ADPr-Ub is limited, we had to drive the forward reaction to over-
come removal of the ADP-ribose moiety by DUBs and other uniden-
tified factors and to fulfill the minimum concentration requirements 
for pull-down with Af1521 macrodomain. We successfully detected 
ADPr-Ub with GST-Af1521 pull-downs by overexpressing DTX2. 
Because only a small percentage of Ub (~1%) retains ADP-ribose, it 
is unlikely that it will stall the general ubiquitination process. The 
effects of ADPr-Ub generated by Deltex might be regulated by NAD+ 
concentration or occur in certain compartments that have high 
Deltex concentrations. Identifying binding motifs that specifically 
recognize ADPr-Ub will help us to understand the functional rele-
vance of this signal.
In summary, we show that the DTC domain from Deltex family 
E3s binds NAD+ and is required for ADP-ribosylation of Ub’s C 
terminus. The conserved Deltex RING-DTC domains enable bind-
ing of E2~Ub via the RING domain and NAD+ via the DTC domain. 
Flexibility of the linker connecting the RD domains facilitates the 
juxtaposition of the thioester bond and NAD+, where, upon release 
of Ub, Ub’s Gly76 carboxylate group is ADP-ribosylated. Like other 
Ub conjugations on Gly76, this signal is dynamic and can be re-
moved by nonspecific DUBs such as USP2. An increasing number of 
studies have shown that bacterial effectors catalyze ADP-ribosylation 
of Ub to block activation by E1. Examples include ADP-ribosylation 
of Ub’s Arg42 and Thr66 by L. pneumophila SidE and Chromobacterium 
violaceum CteC family proteins, respectively (7, 8, 39). Our work 
reveals the role of mammalian Deltex family proteins in catalyzing 
ADP-ribosylation of Ub. These findings should pave the way for 
future studies on understanding the biology of the Deltex family of 
E3s and the functions of ADPr-Ub.
MATERIALS AND METHODS
Cloning and plasmids
Constructs were generated using standard polymerase chain reaction 
techniques and verified by automated sequencing. Codon-optimized 
G-blocks were purchased from Integrated DNA Technologies and 
used as templates for subcloning wild-type variants of DTX1, DTX2, 
DTX3, DTX3L, and PARP9. Mammalian Gene Collection (MGC) 
sequence-verified complementary DNA (cDNA) (Dharmacon 
MHS6278- 211690540) was used as template to subclone the region 
of the gene encoding the RD domains of DTX4. RD domains com-
prise residues 388-C of DTX1, residues 390-C of DTX2, residues 
148-C of DTX3, residues 544-C of DTX3L, and residues 387-C of 
DTX4. Unless otherwise specified, proteins are from human. For 
bacterial expression, DTX variants were cloned into pABLO to-
bacco etch virus (TEV), a modified form of pGEX4T-3 (GE Health-
care) containing an N-terminal GST tag, followed by a TEV cleavage 
site, a second ribosomal binding site, and a second multiple cloning 
site, or pRSF_Duet TEV, a modified form of pRSF_Duet-1 (Novagen) 
containing a TEV cleavage site following the hexahistidine tag. To 
generate DTX3L-FL–PARP9 complex from baculovirus, DTX3L 
was subcloned into pGEX4T-1 TEV (GE Healthcare), in which a 
TEV protease cleavage site replaces the thrombin site. Subsequently, 
GST-DTX3L was subcloned into pACEBAC1 vector. Full-length 
codon-optimized PARP9 was cloned into pACEBAC1 vector with 
an N-terminal noncleavable 6× His-tag. A multigene expression cas-
sette containing GST-DTX3L/His-PARP9 was then constructed by 
using I-Ceu1 and BstX1 restriction sites. EmBacY cells were trans-
formed with the resulting pACEBAC1 GST-DTX3L/His-PARP9 
construct to obtain a bacmid for Sf9 insect cell infection and protein 
expression. For fluorescent labeling, Gly-Gly-Ser-Cys-Ub was cloned 
into a modified version of pGEX4T-1 (GE Healthcare) in which a 
noncleavable hexahistidine tag precedes the glutathione tag, and a 
TEV cleavage site is present instead of thrombin. For mammalian 
expression, native DTX1 (NM004416) and DTX2 (NM020892) were 
cloned into pcDNA3 with an N-terminal Myc tag.
Bacterial plasmids for DUBs were obtained from Addgene: USP5 
(a gift from C. Arrowsmith; Addgene plasmid no. 25299), USP7 (a 
gift from T. Sixma; Addgene plasmid no. 63573), USP21 (a gift from 
C. Arrowsmith; Addgene plasmid no. 25147), vOTU amino acids 1 
to 183 (a gift from D. Komander; Addgene plasmid no. 61589), 
OTUB1 (a gift from C. Wolberger; Addgene plasmid no. 26959), 
OTUD3 (a gift from D. Komander; Addgene plasmid no. 61411), and 
OTULIN (a gift from D. Komander; Addgene plasmid no. 61464). 
USP2 amino acid 260-C was constructed synthetically (codon- 
optimized G-blocks from Integrated DNA Technologies), and YUH1 
and AMSH as described previously (40, 41).
Protein expression and purification
Protocols for generating UbcH5B variants (42), Arabidopsis thaliana 
Uba1 (24), hexahistidine-tagged human Uba1 (43), Ub variants (24, 44), 
Tyr371-phosphorylated c-CBL (residues 47 to 435) (42), stably con-
jugated UbcH5B C85S–Ub (24), UbcH5B C85K–Ub (45), GST-Af1521 
(46), USP2 (29), USP7 (47), vOTU (48), OTUB1 (49), OTUD3 (50), 
OTULIN (51), YUH1 (40), and AMSH (41) have been described pre-
viously. PARP1-His purification was as described (52) but without 
size exclusion chromatography.
Proteins were expressed in Escherichia coli BL21(DE3) Gold cells. 
Cultures were grown in Luria-Bertani (LB) medium at 37°C to an 
OD600 (optical density at 600 nm) of 0.6 to 0.8 and induced with 
0.2 mM isopropyl -d-1-thiogalactopyranoside (IPTG) at 20°C for 
12 to 16 hours, or cultures were grown in LB-based autoinduction 
medium (Formedium) supplemented with 0.5% glycerol. 15N-labeled 
DTX1-RD and 15N-labeled Ub were obtained from M9 minimal 
medium as described previously (40, 53).
Cells were harvested by centrifugation and lysed with a micro-
fluidizer. Cells expressed with a GST-tag were resuspended in 50 mM 
tris-HCl (pH 8.0), 200 mM NaCl, and 5 mM -mercaptoethanol 
(BME). Cells expressed with a hexahistidine or hexahistidine-maltose 
binding protein (MBP) tag were resuspended in 25 mM tris-HCl 
(pH 7.6), 200 mM NaCl, 10 mM imidazole, and 5 mM BME. Cell 
lysates were cleared by high-speed centrifugation. The clarified 
lysates were applied to glutathione affinity or Ni2+-agarose, depending 
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on the tag system, and incubated for 1 to 2 hours on a rotary shaker 
at 4°C. The beads were washed in buffers similar to the lysis buffer; 
GST-tagged proteins were eluted in 50 mM tris-HCl (pH 8.0), 
200 mM NaCl, 1 mM dithiothreitol (DTT), and 10 mM glutathione, and 
His-tagged proteins were eluted in 25 mM tris-HCl (pH 7.6), 
200 mM NaCl, 5 mM BME, and 200 mM imidazole. Tagged pro-
teins were buffer exchanged into 150 mM NaCl, 25 mM tris-HCl 
(pH 7.6), and 1 mM DTT before snap-freezing in liquid nitrogen 
and storage at −80°C.
For removal of tags, protein samples were dialyzed against 25 mM 
tris-HCl (pH 7.6), 150 mM NaCl, and 5 mM BME overnight at 4°C 
in the presence of TEV protease except for Gly-Gly-Ser-Cys-Ub. 
The proteins of interest were separated from the affinity tags or 
the remaining uncleaved proteins by applying the dialyzed and 
cleaved samples onto the same resin and collecting the flowthrough. 
GGSC-Ub was cleaved with TEV from a glutathione agarose col-
umn in 50 mM tris-HCl (pH 8.0), 200 mM NaCl, and 5 mM DTT 
using a peristaltic pump-driven circular system. Further purifica-
tion was performed by size exclusion chromatography on a Superdex 
75 column (GE Healthcare) and pre-equilibrated in 25 mM tris-HCl 
(pH 7.6), 150 mM NaCl, and 1 mM DTT. Protein concentrations were 
determined either by measurement of the absorbance at 280 nm 
based on molar extinction coefficients calculated from the relevant 
sequences using Expasy’s ProtParam or by Bradford assay using 
bovine serum albumin (BSA) as a standard.
For protein expression in Sf9 insect cells, cells were lysed by son-
ication, and GST-DTX3L/His-PARP9 was purified by Ni-NTA 
affinity purification, followed by glutathione-sepharose affinity puri-
fication in buffers as described above. Recombinant full-length 
human PARP9 was purchased from Abcam (ab79665).
Crystallization of DTX1-RD
Purified DTX1-RD (~10 mg/ml) was screened by sitting drop vapor 
diffusion in a range of commercially available screens. Crystals of 
DTX1-RD were obtained in BCS™ condition 44 (Molecular Dimen-
sions). Crystals of DTX1-RD in complex with NAD+ were obtained 
by co-crystallizing DTX1-RD and 2 mM NAD+ in JCSG+™ condition 
59 (Qiagen).
Data collection, structure determination, and refinement
Data were collected at Diamond Light Source stations I04 and I04-1 
and processed by the automatic XIA2 pipeline (54) using Auto-
PROC (55) for DTX1-RD and DIALS (56) for DTX1-RD-NAD+ 
complex. The structure of DTX1-RD was determined using the 
single- wavelength anomalous scattering (SAS) protocol of Auto- 
Rickshaw, the European Molecular Biology Laboratory (EMBL)–
Hamburg automated crystal structure determination platform (57), 
with the output: “The input diffraction data were prepared and con-
verted for use in Auto-Rickshaw using programs in the CCP4 suite 
(58). Structure factor amplitudes (FA) values were calculated using 
the program SHELXC (59). On the basis of an initial analysis of the 
data, the maximum resolution for substructure determination and 
initial phase calculation was set to 3.85 Å. All the eight heavy atoms 
requested were found using the program SHELXD (60). The correct 
hand for the substructure was determined using the programs ABS 
(61) and SHELXE (62). Initial phases were calculated after density 
modification using the program SHELXE (62). The initial phases 
were improved using density modification and phase extension to 
1.98-Å resolution using the program RESOLVE (63). A total of 
47.28% of the model was built using the program ARP/wARP 
(64, 65).” The DTX1-RD-NAD+ complex structure was determined 
by rigid body positioning of the apo model into the isomorphous 
dataset. The structures were refined in PHENIX (66) or BUSTER- 
TNT (version 2.10.3, Global Phasing, UK) and manually inspected 
and manipulated in Coot (67). Validation of the refined structures 
was performed using Coot and MolProbity (68). Structural fig-
ures were made in PyMOL, and sequence alignments were made in 
Aline (69).
Generation of fluorescently labeled Ub
A twofold molar excess of IRDye 800CW Maleimide (LI-COR Bio-
sciences) was incubated with GGSC-Ub for 2.5 hours at room tem-
perature in the dark. Excess dye was removed by passing over two 
Zeba Spin Desalting Columns (Thermo Fisher Scientific) consecu-
tively. The protein concentration of the labeled Ub was estimated 
on the basis of a 95% recovery rate per Zeba column pass. Labeled 
Ub was subsequently mixed with a 30-fold molar excess of unlabeled 
GGSC-Ub to generate a working stock of fluorescently labeled Ub 
(F-Ub) for assays.
Ub ADP-ribosylation assays
Reactions were performed in 50 mM tris-HCl (pH 7.6), 50 mM 
NaCl, 5 mM MgCl2, 5 mM ATP, 0.2 M A. thaliana Uba1, 2 M 
UbcH5B, 20 M Ub, 0.5 M E3, and 200 M NAD+ supplemented 
with 10 M biotin-NAD+ or 32P-NAD+ (40 nCi/l). All reaction 
components except the E3 were assembled and incubated at room 
temperature for 15 to 20 min to allow E2~Ub formation. Subsequently, 
E3 was added to the mixture and incubated at 30°C for 30 min. For 
USP2 treatment, 32P-ADPr-Ub was incubated with USP2 (1 M) at 
room temperature for 1 hour. Reactions were quenched with 2× 
loading dye (LD) containing 500 mM DTT and resolved by SDS-PAGE. 
Reactions using biotin-NAD+ were transferred to a nitrocellulose 
membrane, Ponceau staining was performed on the membrane where 
indicated and completely destained, blocked with 5% BSA, probed 
with mouse anti-Ub (Santa Cruz Biotechnology, cat. no. sc-8017; 
1:1000), and then incubated with DyLight 800 Conjugated NeutrAvidin 
(Thermo Fisher Scientific, cat. no. 22853; 1:10,000) and goat anti- 
mouse IRDye 680LT (LI-COR Biosciences, cat. no. 925-68020; 1:20,000). 
Membranes were scanned on an Odyssey CLx Imaging System 
(LI-COR Biosciences). For radioactive ADP-ribosylation assays, gels 
were dried and visualized by autoradiography or exposed to a phos-
phorimager and scanned using a Typhoon FLA6000. ADP-ribosylation 
assays with UbcH5B-Ub conjugate were performed in the same buffer 
(without Uba1, UbcH5B, and Ub) and contained 5 M DTX1-RD 
and either 20 M UbcH5B C85S–Ub or 20 M UbcH5B C85K–Ub. 
For all assays (ADP-ribosylation, lysine discharge, and autoubiquiti-
nation), concentrations of variants of DTX1-RD, UbcH5B, and Ub 
were normalized to wild-type protein based on densities of InstantBlue 
(Expedeon)–stained protein bands following separation by SDS-PAGE 
using a GS-800 Calibrated Densitometer (Bio-Rad). For UbcH5B–
Ub assays, UbcH5B C85S–Ub and UbcH5B C85K–Ub were normal-
ized to each other based on densities as described above.
ADPr-Ub generation and purification
ADPr-Ub or ADPr-15N-Ub were generated by reacting 0.2 M 
A. thaliana Uba1, 2 M UbcH5B, 100 M Ub or 15N-Ub, 2 M 
DTX1-RD, and 1.25 mM NAD+ at 30°C for 16 hours. Control 
Ub reactions where either DTX1-RD or NAD+ was omitted were 
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prepared in the same manner. For ADPr-Ub or ADPr-15N-Ub, fresh 
0.1 M A. thaliana Uba1 and 1 M Tyr371-phosphorylated c-CBL 
Y368F (residues 47 to 435) (42) were added, and the mixture was 
incubated at 23°C for 1 hour to use up unreacted Ub. ADPr-Ub, 
ADPr-15N-Ub, and control Ub were separated from other components 
using a Superdex75 gel filtration column (GE Healthcare) in 25 mM 
tris-HCl (pH 7.6), 150 mM NaCl, and 1 mM DTT. For USP2-treated 
ADPr-Ub, 1 M USP2 was added to 100 M purified ADPr-Ub, in-
cubated at 23°C for 1 hour, and further purified using a Superdex75 
gel filtration column (GE Healthcare) as described above.
Reactivity of ADPr-Ub
To investigate the reactivity of ADPr-Ub, E2 charging assays were 
performed in 50 mM tris-HCl (pH 7.6), 50 mM NaCl, 5 mM MgCl2, 
5 mM ATP, 1 M A. thaliana Uba1, 10 M UbcH5B, and either 50 M 
ADPr-Ub, 50 M ADPr-Ub treated with USP2, or 50 M wild-type Ub. 
Samples were taken at the indicated time points, quenched with 4× LD, 
resolved by SDS-PAGE, and stained with InstantBlue (Expedeon). 
For ADPr-Ub removal by a panel of DUBs, 1 M DUBs were used.
Lysine discharge assays
UbcH5B (20 M) was charged with human Uba1 (0.4 M) and F-Ub 
(90 M) for 15 min at 23°C in 50 mM tris-HCl (pH 7.6), 50 mM 
NaCl, 5 mM MgCl2, and 5 mM ATP. Charging was stopped by in-
cubating the reaction with 45 mM EDTA for 1 to 2 min. Discharge 
was initiated by the addition of a mixture containing l-lysine 
(300 mM) and DTX1-RD variant (4 M). Reactions were quenched 
at the indicated time points with 4× LD and resolved by SDS-
PAGE. Gels were scanned with an Odyssey CLx Imaging System 
(LI-COR Biosciences). Final concentrations are in parenthesis except 
for UbcH5B and F-Ub, which were 9 and 45 M, respectively.
Quantification and statistical analysis
For lysine discharge assays, Image Studio Lite (LI-COR Biosciences) 
was used to quantify the intensity (I) of each band, and the % 
UbcH5B~F-Ub remaining was calculated as described previously 
(53). Data are presented as an average ± SD based on three or five 
replicates per measurement.
Autoubiquitination assays
Autoubiquitination assays were performed at 23°C in 50 mM tris-
HCl (pH 7.6), 50 mM NaCl, 5 mM MgCl2, 5 mM ATP, inorganic 
pyrophosphatase (0.3 U/ml), creatine kinase (0.3 U/ml) and 5 mM 
creatine phosphate, human Uba1 (0.4 M), UbcH5B variants (10 M), 
Ub or 2TK-Ub variants (50 M), and GST-tagged DTX variants 
(2.7 M). For Fig. 5E, 0, 0.5, or 1 mM NAD+ was added. Reactions 
were quenched at the indicated time points with 2× LD containing 
500 mM DTT and resolved by SDS-PAGE.
PARP1 autoPARylation assay
PARP1 autoPARylation assay was performed at 30°C in 40 mM 
Hepes (pH 7.5), 100 mM NaCl, 4 mM MgCl2, 1 mM Tris(2- 
carboxyethyl)phosphine (TCEP), duplex activating DNA (1 M), 
PARP1-His (1 M), and NAD+ (20 M). After 30 min, reaction was 
quenched with 4× LD and resolved by SDS-PAGE.
Solution NMR experiments
All solution NMR data were acquired on a Bruker Avance III 600 MHz 
spectrometer with a cryogenic triple resonance inverse (TCI) probe. 
Each sample (15N-Ub or 15N-DTX1-RD) was prepared at a con-
centration of ~100 M in NMR buffer [20 mM sodium phosphate 
(pH 7.0), 100 mM NaCl, and 7.5% D2O]. A temperature series rang-
ing from 278 to 317 K was measured at increments of 3 K on a sam-
ple of 15N-Ub to determine the optimal temperature for analysis of 
samples. Given that Gly75 and Gly76 were easily observed at 278 K, 
we used 278 K for most of our analysis. The known peak assignment 
for 15N-Ub at 298 K was traced across the temperature range to as-
sign 1H-15N HSQC spectra for Ub at 278 K. Each 1H-15N HSQC 
spectrum was recorded with 64 complex points and a sweep width 
of 36 parts per million (ppm) in the 15N dimension. All spectra were 
processed with 256 points using Bruker TopSpin version 3.5 patch 
level 7. All spectra were analyzed using CARA and NMRFAM- 
SPARKY (70).
CSPs were calculated as follows
  CSP =  [ (  HA –   HB ) 2 +  ((  NA –   NB ) / 5) 2 ] 1/2 
Cell culture and pull-down experiments
HEK 293 cells were obtained from the American Type Culture Col-
lection, revived and sent for in-house cell line authentication by short 
tandem repeat profiling using GenePrint 10 System (Promega), and 
tested for mycoplasma. HEK293 cells were maintained in Dulbecco’s 
modified Eagle’s medium supplemented with 10% fetal bovine serum, 
2 mM l-glutamine, penicillin (100 U/ml), streptomycin (100 g/ml), 
and gentamicin (10 g/ml). Transfections were performed using 
Lipofectamine 2000 reagent. Cells were harvested 40 hours after 
transfection and lysed in lysis buffer [50 mM tris-HCl (pH 7.6), 
150 mM NaCl, 1% IGEPAL, 1 mM DTT, 1 mM phenylmethylsulfonyl 
fluoride, and protease inhibitor cocktail]. Whole-cell lysate protein 
concentration was measured using Bio-Rad reagent, and similar 
amounts of total protein were incubated with GST-Af1521 (20 g of 
GST-Af1521/10 l of glutathione-agarose beads) for 3 hours at 4°C 
on an end-to-end mixer. Beads were washed with 5 × 500 l of lysis 
buffer and eluted with 1× LD + 250 mM DTT. Eluates were boiled 
at 95°C for 10 min, spun down, and separated by SDS-PAGE. The 
samples were then transferred onto a nitrocellulose membrane us-
ing the Trans-Blot Turbo Transfer System (Bio-Rad), blocked in 5% 
BSA in tris-buffered saline at room temperature for 1 hour, and 
probed with mouse anti-Ub antibody at 4°C overnight as described 
above. The following day, the membrane was washed, incubated 
with goat anti-mouse IRDye800CW (LI-COR Biosciences, cat. no. 
925-32210; 1:20,000), and scanned using an LI-COR Odyssey CLx 
Imaging System.
SAXS experiments
Purified protein was shipped to Diamond Light Source, where it 
was applied onto a Superdex 200 Increase 3.2 column equilibrated 
in buffer containing 25 mM tris-HCl (pH 7.6), 150 mM NaCl, and 
1 mM DTT at 0.16 mg/ml, before being exposed to the x-ray beam 
as part of the standard setup at station B21. Data were analyzed using 
ScÅtter version 3.2h (available from station B21, Diamond Light 
Source). Analysis of the movement of the DTC and RING domains 
in relation to each other was performed by EOM (ensemble optimi-
zation method) (26).
Mass spectrometry
ADPr-Ub (453 M) was reacted with 11 M USP2 in a buffer con-
taining 25 mM Hepes (pH 7), 150 mM NaCl, and 1 mM BME for 
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30 min at room temperature. ADP-ribose standard (400 M) was 
prepared in the same buffer. Samples were quenched in extraction 
solution (methanol, acetonitrile, and water; 5:3:2) at 4°C. Following 
15-min incubation at −20°C, the extracts were centrifuged at 16,100g 
for 10 min at 4°C to remove precipitated protein. LC-MS analysis 
was carried out on the supernatants as previously described (71). 
Identification of ADPr peak was confirmed by comparison of the 
exact mass and the retention time observed using a commercial 
ADPr standard analyzed under the same LC-MS conditions. The ex-
tracted ion chromatograms of ADPr were generated using FreeStyle 
software (Thermo Fisher Scientific).
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/6/38/eabc0418/DC1
View/request a protocol for this paper from Bio-protocol.
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